例如，长期嗜酒会引起酒精性肝炎。
Long-term overuse of alcohol, for example, can cause alcoholic hepatitis.
目的：探讨狗胆对大鼠酒精性肝炎的防治作用。
AIM: To investigate the preventive and therapeutic effects of dog bile on alcohol-related hepatitis in rats.
【译】组织学评分系统对酒精性肝炎患者的预后。
A histologic scoring system for prognosis of patients with alcoholic hepatitis.
方法对72例酒精性肝炎患者的临床资料进行回顾性分析研究。
Methods Carry on retrospective analysis research to the sufferer's clinical data of 72 cases alcoholic hepatitis.
里尔模型：类固醇为重度酒精性肝炎患者的治疗策略的新工具。
The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids.
国际肝病：您能给我们概括介绍一下目前治疗酒精性肝炎的进展吗？
Hepatology Digest: Will you please give us your general over-view of the current progress in the treatment of alcoholic hepatitis?
酒精性肝炎往往导致肝硬化及肝癌，其重症患者短期死亡率相当高。
Alcoholic hepatitis is a serious liver disease that may lead to cirrhosis and carcinoma, and the short-term mortality rate is fairly high in severe patients.
如果不戒酒，大多数酒精性肝炎患者最终将进展为肝硬化并死亡，Dr。
Without abstinence, the majority of people with alcoholic hepatitis eventually develop cirrhosis and die, says Dr.
研究结果发现接受依那西普的中重度酒精性肝炎患者的六个月死亡率显著增高。
Research results found a significantly higher rate of six-month mortality in patients with moderate to severe alcoholic hepatitis who received etanercept.
国际肝病：最近在胃肠病学杂志上发表了酒精性肝炎使用依那西普的临床试验结果，您是作者之一。
Hepatology Digest: Recently, the clinical trial result for the use of Etanercept for alcoholic hepatitis was published in Gastroenterology, and you were one of the authors.
梅奥诊所的一项新的研究发现依那西普药物治疗酒精性肝炎，一种酒精过量导致的急性肝脏炎性改变是无效的。
A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol.
结果喂饲4周时可见轻度酒精性肝炎和酒精性脂肪肝病理改变，12周时酒精性肝炎改变加重并出现了纤维化。
After 12 weeks, alcohol hepatitis were aggravated and fibrosis were observed in pathology. Conclusion These results demonstrate that the alcohol liver disease...
已经有一些研究发现了治疗酒精性肝炎成功的治疗方法，但是在最有效的治疗的用药方法上还没有达成一致的意见。
Several research studies have worked to find a successful treatment for alcoholic hepatitis, but no consensus has been reached on the most effective treatment regimen.
目的：观察酒精性肝炎患者使用还原型谷胱甘肽治疗后肝纤维化指标的改善情况及临床症状、体征、肝功能的变化。
AIM: to observe the changes of hepatic fibrosis index, clinical symptom, physical sign and hepatic function after the patients were treated treatment with reduced glutathione hormone.
他认为这项实验提供了一些可信的想法，它确实放大了炎症反应，所以以它为靶点可能成为治疗酒精性肝炎的一个新手段。
He said the study "gives some credence to the idea that this actually amplifies the inflammation and, therefore, by targeting it, you may have another therapeutic intervention in alcoholic hepatitis."
尽管这种治疗方法，但仍有30- 35%的急性酒精性肝炎患者死于六个月内，因为可的松为基础的治疗仍然效果不足。
Despite this treatment, 30-35% of patients with acute alcoholic hepatitis still die within a six month period, since the cortisone-based treatment remains insufficient.
我在我们医院中看到越来越多的急性酒精性肝炎（日后大都转化为肝硬化）患者，他们会导致各种疾病的发病率和死亡率的升高，同时也消耗掉了许多宝贵的健康资源。
An increasing number of severely ill acute alcoholic hepatitis patients, often superimposed on cirrhosis, are being seen in our hospitals and cause much morbidity, mortality and health service costs.
新的研究包括55个患非酒精性脂肪性肝炎且有胰岛素抵抗或2型糖尿病的患者。
The new study included 55 people with nonalcoholic steatohepatitis and either insulin resistance or type 2 diabetes.
此外，肝脏基金会估计有5%的美国人患非酒精性脂肪性肝炎。
Additionally, the liver foundation estimates that about 5 percent of Americans have NASH.
联合治疗应是未来非酒精性脂肪性肝炎临床试验的范例吗？
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
我们必须认识到所有非酒精性脂肪性肝炎患者发病机制并不是单一的信号途径。
I think that it probably has to do with the fact that the pathogenesis of all patients with non-alcoholic steatohepatitis, is probably not a single way or a single pathway.
图像定量分析表明，酒精性肝病肝纤维化程度重于慢性病毒性肝炎者。
Image-analysis showed that the percentage of fibrous tissues was higher in ALD than that in chronic viral hepatitis at same stage of fibrosis.
观察应用复方二氯醋酸二异丙胺治疗慢性病毒性肝炎合并酒精性肝损伤的临床疗效。
To evaluate the efficacy of diisopropylamine dichloroacetate (Ganle) injection on chronic hepatitis companied with alcoholic liver disease.
酒精性肝损伤已成为继病毒性肝炎后的主要肝损伤病因，因此酒精性肝病的防治已经成为重要的医疗课题。
Alcoholic liver disease has become the main cause of liver injury following the virus hepatitis, and its prevention and cure has become an important medical task.
非酒精性脂肪性肝炎和其他脂肪性肝病的发病机制：四步模型，包括肝硬化进展的脂质释放和肝微梗阻的作用。
The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.
非酒精性脂肪性肝炎（NASH）是一种慢性肝脏疾病，自上世纪八十年代以来逐渐被认识并引起重视。
Non-alcoholic steatohepatitis(NASH)is a chronic liver disease. It is known and thought highly from 1980s last century.
我们及其他研究者最近得出的这一结论适用于多种肝脏疾病，包括乙型慢性病毒性肝炎、丙型慢性病毒性肝炎、酒精性肝病和非酒精性脂肪肝。
We and others have pointed this out recently for several liver diseases, including chronic viral hepatitis B and c, alcoholic liver disease, and non-alcoholic fatty liver disease.
方法选择符合条件的72例非酒精性脂肪性肝炎患者，随机分为治疗组和对照组。
Methods 72 patients with nonalcoholic fatty liver diseases were randomly divided into two groups.
目的观察甜菜碱对实验性非酒精性脂肪性肝炎（NASH）大鼠的保护作用，并探讨其可能机制。
ObjectiveTo investigate the protective effects of betaine on experimental NASH in rats and the possible mechanisms of the protective effects.
目的观察甜菜碱对实验性非酒精性脂肪性肝炎（NASH）大鼠的保护作用，并探讨其可能机制。
ObjectiveTo investigate the protective effects of betaine on experimental NASH in rats and the possible mechanisms of the protective effects.
应用推荐